Needham reiterated coverage on Immuneering Corporation with a new price target
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously